OMEROS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.05 USD | -4.98% |
|
-18.88% | -6.73% |
| Apr. 01 | Tranche Update on Omeros Corporation's Equity Buyback Plan announced on April 1, 2024. | CI |
| Apr. 01 | Omeros Corporation announces an Equity Buyback for $50 million worth of its shares. | CI |
Chart calendar Omeros Corporation
da08999c.53KwkZCRd5A7NvNKEHF6CSaJB2XpIYz1urB4TMwj71c.10WE38HoHcpyfosDXhIAQRS8MCSHSOSH1dpVfKJaghC_C_7e4KUW5nNjsg~88e7de0d7f7c70dd34a29e6df7270507
Upcoming events on Omeros Corporation
Past events on Omeros Corporation
| 2024-04-01 04:30 pm | Q4 2023 Earnings Call |
| 2024-04-01 04:02 pm | Q4 2023 Earnings Release |
| 2024-02-22 07:45 pm | American Society for Transplantation and Cellular Therapy and Center for International Blood and Mar |
| 2023-12-11 09:00 pm | American Society of Hematology Meeting - Abstract #4082 |
| 2023-12-10 09:00 pm | American Society of Hematology Meeting - Abstract Number :3543 |
| 2023-12-10 08:00 pm | American Society of Hematology Meeting - Abstract #573 |
| 2023-11-09 04:30 pm | Q3 2023 Earnings Call |
| 2023-11-09 04:02 pm | Q3 2023 Earnings Release |
| 2023-10-16 08:30 am | NARSOPLIMAB Phase 3 Study Results Call |
| 2023-08-09 08:30 am | Q2 2023 Earnings Call |
| 2023-08-09 08:00 am | Q2 2023 Earnings Release |
| 2023-06-23 01:00 pm | Annual General Meeting |
| 2023-06-11 03:45 am | European Hematology Association Hybrid Congress - Abstract No:LB2714 |
| 2023-06-09 12:00 pm | European Hematology Association Hybrid Congress - Abstract No: P787 |
| 2023-05-09 04:30 pm | Q1 2023 Earnings Call |
| 2023-05-09 04:02 pm | Q1 2023 Earnings Release |
| 2023-03-13 04:30 pm | Q4 2022 Earnings Call |
| 2023-03-13 04:02 pm | Q4 2022 Earnings Release |
| 2022-12-12 06:00 pm | American Society of Hematology Meeting - Abstract No - 3808 |
| 2022-12-11 06:00 pm | American Society of Hematology Meeting - Abstract 2570 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 112 110 1.48% | 73,8 78,1 -5.47% | 112 111 0.95% | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 0,00 - | -109 -102 -6.57% | -172 0,41 -42182.49% | -162 -158 -2.7% | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -63,4 -51,2 -23.84% | -111 -110 -0.42% | -174 -52,4 -231.55% | -163 -162 -1.16% | -165 -171 3.87% | -159 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -84,5 -72,3 -16.86% | -150 -150 -0.09% | -192 -84,2 -127.54% | -182 -111 -64.43% | -175 -150 -17% | -157 |
|
Net income Million USD | Released Forecast Spread | -84,5 -72,3 -16.86% | -138 -146 5.62% | 194 -84,1 330.92% | 47,4 -112 142.41% | -118 -147 19.99% | -138 |
|
EPS USD | Released Forecast Spread | -1,71 -1,52 -12.5% | -2,41 -2,51 4.17% | 3,12 -1,09 384.99% | 0,76 -1,81 141.96% | -1,88 -2,28 17.36% | -2,09 |
| Announcement Date | 02/03/20 | 01/03/21 | 01/03/22 | 13/03/23 | 01/04/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 31,9 30,8 3.4% | 0,00 0,00 - | 0,00 0,00 - | 0,00 2,79 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -42,6 110 -138.58% | ||||||||||||
|
EBIT Million USD | Released Forecast Spread | -42,9 18,8 -328.46% | -35,0 -44,4 21.12% | -37,4 -40,0 6.5% | -50,8 -36,8 -38.14% | -40,1 -41,0 2.12% | -35,7 -39,1 8.71% | -40,9 -38,5 -6.15% | -48,2 -43,2 -11.59% | -39,8 -46,3 14.02% | -36,2 | -39,1 | -42,0 | -42,3 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -47,3 2,33 -2127.34% | -33,0 -43,3 23.76% | -41,7 -36,0 -15.82% | -54,8 -36,0 -52.28% | -46,0 -29,3 -57.16% | -39,7 -35,3 -12.42% | -44,3 -33,7 -31.44% | -51,7 -42,6 -21.26% | -39,3 -40,8 3.71% | -33,3 | -39,0 | -41,6 | -42,9 |
|
Net income Million USD | Released Forecast Spread | 281 2,33 11925.2% | -33,0 -43,3 23.76% | -30,8 -39,2 21.22% | -17,5 -37,8 53.88% | 129 -34,7 471.02% | -33,7 -35,3 4.53% | -37,3 -41,7 10.67% | -37,8 -42,6 11.38% | -9,07 -38,4 76.39% | -33,7 | -34,0 | -36,3 | -34,0 |
|
EPS USD | Released Forecast Spread | 4,48 0,21 2002.89% | -0,53 -0,62 13.82% | -0,49 -0,63 22.2% | -0,28 -0,56 49.89% | 2,05 -0,57 457.27% | -0,54 -0,54 0.06% | -0,59 -0,57 -3.51% | -0,60 -0,65 6.98% | -0,15 -0,56 72.97% | -0,56 | -0,53 | -0,54 | -0,50 |
| Announcement Date | 01/03/22 | 10/05/22 | 09/08/22 | 09/11/22 | 13/03/23 | 09/05/23 | 09/08/23 | 09/11/23 | 01/04/24 | - | - | - | - |
More events
Past sector events for Omeros Corporation
| 2024-04-17 | BEIJING KAWIN TECHNOLOGY SHARE-HOLDING CO., LTD.: Q1 2024 Earnings Release (Projected) |
| 2024-04-17 | JIANGSU YAHONG MEDITECH CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-12 | SINOCELLTECH GROUP LIMITED: Q4 2023 Earnings Release |
| 2024-04-10 07:00 am | NURIX THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-04-08 | MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-02 03:06 am | TAIMED BIOLOGICS INC.: March 2024 Sales and Revenue Release |
| 2024-03-31 | PEPTRON, INC.: Q4 2023 Earnings Release (Projected) |
| 2024-03-31 | BIONEER CORPORATION: Q4 2023 Earnings Release (Projected) |
| 2024-03-29 08:30 am | INNOCARE PHARMA LIMITED: Q4 2023 Earnings Release |
| 2024-03-28 | BIO-THERA SOLUTIONS, LTD.: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- OMER Stock
- Calendar Omeros Corporation
